Scholarlink

<p>Interventional brachytherapy, such as iodine-125(<sup>125</sup>I), has improved the survival of obstructive late-stage esophageal cancer patients. However, most patients experience radioresistance after <sup>125</sup>I brachytherapy. It is key to decipher the underlying mechanism of <sup>125</sup>I radioresistance. In this study, we identified an endoplasmic reticulum-associated protein, P4HA2, which is upregulated and mediates resistance to <sup>125</sup>I treatment. Mechanistically, P4HA2 enhances mitochondrial autophagy (mitophagy) via the PINK1/parkin pathway by binding to ATAD3A. Clinically, high expression of P4HA2 correlates with shorter overall survival and predicts poor prognosis with <sup>125</sup>I brachytherapy. Moreover, the expression of P4HA2 is epigenetically increased by IGF2BP2 in an m<sup>6</sup>A-dependent manner. Notably, targeting P4HA2 with siRNA-based biocompatible nanomedicines significantly sensitizes ESCC to <sup>125</sup>I brachytherapy. Collectively, our results show the molecular mechanism of mitophagy-mediated <sup>125</sup>I radioresistance, which provides a potential therapeutic target and combinatorial strategy.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

P4HA2 interacted with ATAD3A to modulate PINK1/parkin-dependent mitophagy and 125I brachytherapy sensitization in esophageal carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Xijuan Yao,
  • Cheng Feng,
  • Xing Huang,
  • Songzhe Wu,
  • Shuting Lu,
  • Yang Gao,
  • Tong Sun,
  • Xiaxing Bai,
  • Chenghui Li,
  • Kaizhi Jia,
  • Xue Han,
  • Zhongkai Wang,
  • Binda Chen,
  • Xiaobin Wang,
  • Jinhe Guo,
  • Jian Lu

摘要

Interventional brachytherapy, such as iodine-125(125I), has improved the survival of obstructive late-stage esophageal cancer patients. However, most patients experience radioresistance after 125I brachytherapy. It is key to decipher the underlying mechanism of 125I radioresistance. In this study, we identified an endoplasmic reticulum-associated protein, P4HA2, which is upregulated and mediates resistance to 125I treatment. Mechanistically, P4HA2 enhances mitochondrial autophagy (mitophagy) via the PINK1/parkin pathway by binding to ATAD3A. Clinically, high expression of P4HA2 correlates with shorter overall survival and predicts poor prognosis with 125I brachytherapy. Moreover, the expression of P4HA2 is epigenetically increased by IGF2BP2 in an m6A-dependent manner. Notably, targeting P4HA2 with siRNA-based biocompatible nanomedicines significantly sensitizes ESCC to 125I brachytherapy. Collectively, our results show the molecular mechanism of mitophagy-mediated 125I radioresistance, which provides a potential therapeutic target and combinatorial strategy.